Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 19;17(6):4907–4913. doi: 10.3892/ol.2019.10163

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Lin et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Prognostic values of KMT5A and CDH1 for patients with ccRCC, assessed by Kaplan-Meier analyses. (A) High levels of CDH1 were observed in 30.3% of the high-KMT5A group in comparison with 69.0% in the low-KMT5A group. (B) A negative correlation was revealed between the expression levels of KMT5A and CDH1 in ccRCC tissues (r=−0.6506; P<0.001). (C) The patients with ccRCC who exhibited high CDH1 expression were associated with longer OS time compared with the low CDH1 expression group. (D) Patients who had high KMT5A as well as low CDH1 expression levels were associated with the poorest prognosis (the shortest OS time), whereas those with low KMT5A and high CDH1 expression levels had the best prognosis. The ccRCC data was obtained from The Cancer Genome Atlas database (https://tcga-data.nci.nih.gov/publications/tcga). ccRCC, clear cell renal cell carcinoma; KMT5A, N-lysine methyltransferase KMT5A; CDH1, cadherin-1; OS, overall survival.